ScreenerHero

LTGO Latigo Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · latigobio.com
15.52USD-4.55%Mkt Cap: 1.03B $P/E: —

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.03B USD
Enterprise Value1.34B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-109.17M USD
Revenue/Share—
Last Price15.52 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees66
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.78
PEG—
EV/EBITDA-11.97
EV/Revenue—
P/S—
P/B-0.06
EPS (TTM)-2.47
EPS (Forward)-2.09
52W Range
15.272% of range25.93
52W High25.93 USD
52W Low15.27 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE47.12%
ROA-144.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-97.56M USD
CapEx (TTM)136.00K USD
FCF Margin—
FCF Yield—
Net Debt-23.75M USD
Net Debt/EBITDA0.21
Balance Sheet
Debt/Equity-0.00
Current Ratio1.15
Quick Ratio1.07
Book Value/Sh-279.37 USD
Cash/Share0.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)52.25 USD
Upside (mean)+236.7%
Target Range36.00 USD – 73.00 USD
36.00+236.7% to mean73.00
# Analysts4
Ownership
Shares Out.66.30M
Float21.74M
Insiders4.98%
Institutions79.04%
Short Interest
Short Ratio2.3d
Short % Out.0.68%
Shares Short449.96K
Short (prev mo.)134.47K
Technical
SMA 5020.77 (-25.3%)
SMA 20020.77 (-25.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)364.23K
Avg Vol (10d)430.12K
Technical Indicators
RSI (14)32.6
MACD-1.4979
MACD Signal-1.0288
MACD Hist.-0.4691
BB Upper25.20 USD
BB Middle19.45 USD
BB Lower13.69 USD
BB Width59.18%
ATR (14)1.529 USD
Vol Ratio (20d)0.55x